Clinical trials: Malignant Tumor Liver
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Liver Tumor
Is Thoracic Paravertebral Block a Better Option Than Conscious Sedation for PRFA of Liver Tumors
Percutaneus radiofrequency ablation (RFA) of liver tumors causes acute pain during the periooperative setting. In order to facilitate tumor access, patient should collaborate with a surgeon during the procedurę, therefore should…
- Trial name
- NCT04241887
- Testing
- thoracic paravertebral blockade, local anaesthesia
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- University of Warmia and Mazury
Malignant Liver Neoplasm
Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study
This phase II trial studies how well software-aided imaging works in confirming tumor coverage with ablation (the removal or destruction of a body part or tissue or its function) on patients with liver tumors.
- Trial name
- NCT04083378
- Testing
- Ablation Therapy, Image-Guided Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Hepatocellular Carcinoma, Liver Cancer
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, HCC
- Trial name
- TRAVERSE (NCT01387555)
- Testing
- JX-594 recombinant vaccina GM-CSF, Best Supportive Care
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 129 people
- Sponsor
- Jennerex Biotherapeutics
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
- Conditions
- Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma
- Trial name
- NCT02762721
- Where
- 6 sites in United States, Italy
- Volunteers
- 131 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic…
- Trial name
- NCT00849264
- Testing
- chemotherapy with endostar, treatment with CBP and 5-FU, treatment with endostar, CBP and 5-FU
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan.
- Trial name
- NCT06354387
- Testing
- Alectinib (Alecensa), Nivolumab (Opdivo)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- China Medical University Hospital
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Liver Tumor; Surgery, Primary Liver Tumor, Metastatic Liver
Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection, A Non-inferiority Randomized Controlled Trial
Liver resection is a major surgery that can be associated with significant intraoperative blood loss and blood transfusion. Among high-volume centers, median intraoperative blood loss ranges between 300-800 ml.
- Conditions
- Liver Tumor; Surgery, Primary Liver Tumor, Metastatic Liver, Primary Liver Cancer, Liver Resection
- Trial name
- NCT06905015
- Testing
- High SVV-guided fluid management, Low CVP-guided fluid management
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- Chiang Mai University
Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
Multimodal thermal therapy (MTT), as an initiative integration of cryotherapy and radiofrequency heating, has been applied to treat various solid tumors.
- Trial name
- NCT07159048
- Testing
- Multimodal Tumor Thermal Therapy System, Radiofrequency Ablation System or Microwave Ablation System
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Solid Tumor
Study of EOC317 in Chinese Patients With Advanced Solid Tumors
This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.
- Trial name
- NCT03583125
- Testing
- EOC317
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Liver Cancer
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
This study was designed to confirm that the surgeon is able to perform surface registration of standard liver features used as landmarks during a scheduled laparoscopic liver procedure.
- Trial name
- NCT01237990
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pathfinder Therapeutics
Hepatocellular Carcinoma
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
The study is a prospective, phase II trial single arm, historical control aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L(P) System, in combination with sorafenib in patient with advanced HCC.
- Trial name
- NCT03606590
- Testing
- NovoTTF-100L(P) device, Sorafenib
- Where
- 8 sites in Czechia, France and 4 more
- Volunteers
- 25 people
- Sponsor
- NovoCure Ltd.
Hepatocellular Carcinoma
Tumor Growth Factors in Hepatocellular Carcinoma
Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells.
- Trial name
- NCT00764140
- Testing
- tumor growth factor concentration
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions.
- Conditions
- Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
- Trial name
- NCT02156739
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Colorectal Cancer Liver Metastasis
3D Bioprinted Models for Predicting Chemotherapy Response in Colorectal Cancer With/Without Liver Metastases
The therapeutic regimens of adjuvant and neoadjuvant chemotherapy for colorectal cancer (CRC) remain largely relied on clinical experience, and thus preclinical models are needed to guide individualized medicine.
- Trial name
- NCT04755907
- Testing
- surgical resection, adjuvant chemotherapy, neoadjuvant therapy
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Primary or Metastatic Tumor in the Liver Parenchyma
Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI
This is an exploratory, national, single-center, open-label study, being conducted at the Institute of Education and Research of the Syrian-Lebanese Hospital in collaboration with the Radiology Institute, the Heart Institute of…
- Trial name
- NCT02692365
- Testing
- Magnetic Resonance + hemodynamic + infusion of gadolinium
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital Sirio-Libanes
Malignant Tumor of Small Intestine Metastatic to Liver
Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science
Traditional Chinese medicine (TCM) syndrome is a core foundation of disease knowledge, clinical diagnosis and treatment and curative effect evaluation in TCM.
- Trial name
- NCT03189992
- Testing
- Bushen-Jianpi Dedoction, cinobufotalin injection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine